Loading...
•
Mar 31, 2021
EyePoint Pharmaceuticals Q1 2021 Earnings Report
EyePoint Pharmaceuticals reported financial results for Q1 2021 and highlighted recent corporate developments.
Key Takeaways
EyePoint Pharmaceuticals reported a productive first quarter with a solid commercial performance and advancements in their pipeline, including the initiation of the Phase 1 DAVIO clinical trial for EYP-1901 and the completion of a $115.1 million follow-on financing.
First patient dosed in the EYP-1901 DAVIO study for wet AMD in January, with initial data expected in Q4 2021.
Completed a $115.1 million follow-on financing in February 2021.
Net product revenues increased by 45% to $6.8 million compared to $4.7 million in Q1 2020.
Asia partner Ocumension Therapeutics' new drug application (NDA) for OT-401 (YUTIQ) was accepted for review by the National Medical Products Administration (NMPA).
Revenue by Segment
Forward Guidance
EyePoint expects its cash on hand and net cash inflows from product sales to fund current and planned operations through the end of 2022.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...